Malaga Cove Capital LLC Increases Holdings in Danaher Co. (NYSE:DHR)

Malaga Cove Capital LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 15.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,339 shares of the conglomerate’s stock after acquiring an additional 591 shares during the quarter. Malaga Cove Capital LLC’s holdings in Danaher were worth $1,004,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Stokes Family Office LLC grew its position in Danaher by 8.0% during the 4th quarter. Stokes Family Office LLC now owns 2,225 shares of the conglomerate’s stock worth $515,000 after acquiring an additional 165 shares during the last quarter. Bordeaux Wealth Advisors LLC grew its holdings in shares of Danaher by 9.4% in the fourth quarter. Bordeaux Wealth Advisors LLC now owns 4,241 shares of the conglomerate’s stock worth $981,000 after purchasing an additional 363 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Danaher by 151.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,265 shares of the conglomerate’s stock worth $1,681,000 after buying an additional 4,371 shares during the period. SouthState Corp raised its holdings in Danaher by 3.3% during the 4th quarter. SouthState Corp now owns 94,413 shares of the conglomerate’s stock valued at $21,842,000 after buying an additional 3,008 shares during the last quarter. Finally, Accretive Wealth Partners LLC boosted its position in Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after buying an additional 414 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.6 %

Shares of NYSE:DHR traded up $1.54 on Friday, hitting $248.38. 1,787,817 shares of the company traded hands, compared to its average volume of 2,914,990. The stock has a 50 day simple moving average of $248.48 and a 200-day simple moving average of $232.27. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The company has a market cap of $183.97 billion, a PE ratio of 42.10, a PEG ratio of 3.82 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the business earned $2.36 EPS. As a group, research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were issued a $0.27 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,273 shares of company stock worth $26,813,819. 11.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Raymond James raised their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Royal Bank of Canada raised their price target on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. KeyCorp lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.